154 related articles for article (PubMed ID: 14716035)
1. Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis.
O'Boyle KP; Murigeppa A; Jain D; Dauber L; Dutcher JP; Wiernik PH
Med Oncol; 2003; 20(4):379-84. PubMed ID: 14716035
[TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.
Nabhan C; Rundhaugen L; Jatoi M; Riley MB; Boehlke L; Peterson LC; Tallman MS
Ann Oncol; 2004 Aug; 15(8):1231-6. PubMed ID: 15277263
[TBL] [Abstract][Full Text] [Related]
4. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide.
Saviola A; Luppi M; Potenza L; Morselli M; Ferrari A; Riva G; Torelli G
Br J Haematol; 2003 Nov; 123(4):752-3. PubMed ID: 14616990
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
[TBL] [Abstract][Full Text] [Related]
6. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
7. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
8. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia.
Tack DK; Letendre L; Kamath PS; Tefferi A
Bone Marrow Transplant; 2001 Nov; 28(9):895-7. PubMed ID: 11781652
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Stadtmauer EA
Curr Oncol Rep; 2002 Sep; 4(5):375-80. PubMed ID: 12162910
[TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and..
Gordon LI
Bone Marrow Transplant; 2001 Nov; 28(9):811-2. PubMed ID: 11781639
[No Abstract] [Full Text] [Related]
12. Possible association between Budd-Chiari Syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia.
Kurt M; Shorbagi A; Altundag K; Elkiran T; Güllü I; Kansu E
Am J Hematol; 2005 Nov; 80(3):213-5. PubMed ID: 16247755
[TBL] [Abstract][Full Text] [Related]
13. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Giles FJ; Kantarjian HM; Kornblau SM; Thomas DA; Garcia-Manero G; Waddelow TA; David CL; Phan AT; Colburn DE; Rashid A; Estey EH
Cancer; 2001 Jul; 92(2):406-13. PubMed ID: 11466696
[TBL] [Abstract][Full Text] [Related]
14. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
McKoy JM; Angelotta C; Bennett CL; Tallman MS; Wadleigh M; Evens AM; Kuzel TM; Trifilio SM; Raisch DW; Kell J; DeAngelo DJ; Giles FJ
Leuk Res; 2007 May; 31(5):599-604. PubMed ID: 16959316
[TBL] [Abstract][Full Text] [Related]
15. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Giles F; Garcia-Manero G; O'Brien S; Estey E; Kantarjian H
Acta Haematol; 2002; 108(3):164-7. PubMed ID: 12373091
[No Abstract] [Full Text] [Related]
16. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
17. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.
Rajvanshi P; Shulman HM; Sievers EL; McDonald GB
Blood; 2002 Apr; 99(7):2310-4. PubMed ID: 11895761
[TBL] [Abstract][Full Text] [Related]
18. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of gemtuzumab-associated hepatic sinusoidal occlusion syndrome after hematopoietic stem cell transplant.
Aplenc R; Vachani A; Han P; Glatfelter W; Sievers EL
Acta Haematol; 2003; 110(4):207-10. PubMed ID: 14663169
[No Abstract] [Full Text] [Related]
20. Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin).
Bastie JN; Suzan F; Garcia I; Isnard F; de Revel T; Terre C; Mayeur D; Abraham C; Lavielle R; Castaigne S
Br J Haematol; 2002 Mar; 116(4):924. PubMed ID: 11886404
[No Abstract] [Full Text] [Related]
[Next] [New Search]